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Abstract
Background: Frataxin, the mitochondrial protein deficient in Friedreich ataxia, a rare autosomal recessive neurodegen-
erative disorder, is thought to be involved in multiple iron-dependent mitochondrial pathways. In particular, frataxin plays
an important role in the formation of iron-sulfur (Fe-S) clusters biogenesis.
Methodology/Principal Findings: We present data providing new insights into the interactions of mammalian frataxin with
the Fe-S assembly complex by combining in vitro and in vivo approaches. Through immunoprecipitation experiments, we
show that the main endogenous interactors of a recombinant mature human frataxin are ISCU, NFS1 and ISD11, the
components of the core Fe-S assembly complex. Furthemore, using a heterologous expression system, we demonstrate that
mammalian frataxin interacts with the preformed core complex, rather than with the individual components. The
quaternary complex can be isolated in a stable form and has a molecular mass of <190 kDa. Finally, we demonstrate that
the mature human FXN81–210 form of frataxin is the essential functional form in vivo.
Conclusions/Significance: Our results suggest that the interaction of frataxin with the core ISCU/NFS1/ISD11 complex most
likely defines the essential function of frataxin. Our results provide new elements important for further understanding the
early steps of de novo Fe-S cluster biosynthesis.
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Introduction
Human frataxin is the protein deficient in Friedreich ataxia
(FRDA), a devastating autosomal recessive neurodegenerative
disease associated with hypertophic cardiomyopthy, affecting 1/
40,000 in the caucasian population [1,2]. Frataxin is a highly
conserved mitochondrial protein from bacteria to humans [2,3].
Genetic and biochemical studies support a role of frataxin as a
multifunctional protein in different iron-dependent mitochondrial
pathways [2,3], through its ability to bind iron in vitro [4,5] and to
deliver iron to different acceptors [6,7]. Moreover, binding of iron
can trigger frataxin oligomerization in vitro,ap r o c e s st h a tw a s
proposed to scavenge toxic iron in a bioavailable form and to be
essential for frataxin function [8]. Both monomeric and oligomeric
forms of frataxin were shown to interact with various potential iron
acceptors. Frataxin was shown to interact in vitro with ferrochelatase
and to provide the iron that is needed in the last step of heme
biosynthesis [7,9]. Frataxin was also proposed to interact with
mitochondrial aconitase, a Fe-S-containing protein, providing
protection against the disassembly of the Fe-S cluster by facilitating
iron transfer to aconitase [10]. Similarly, and more extensively, both
monomericandoligomericformsoffrataxinwereproposedtobe the
iron donor protein for de novo Fe-S cluster biosynthesis [6,11–16].
Fe-S clusters are critical prosthetic groups present in proteins
involved inessentialcellularprocessesranging fromnucleargenome
stability, protein translation to mitochondrial metabolism [17].
Within the past decade, the biogenesis of Fe-S proteins has been
extensively studied in bacteria and yeast demonstrating that it is a
complex process involving multiple highly conserved components
[17,18]. De novo Fe-S cluster assembly, a mitochondrial process in
eukaryotes, relies on the assembly of a Fe-S cluster on a scaffold
protein (IscU (bacteria), Isu1 (yeast), ISCU (mammalian)) from
inorganic iron and sulfur, followed by the transfer of the scaffold-
bound Fe-S cluster to the target apoproteins. Both the synthesis and
the final transfer to apoproteins require the help of additional
proteins. The sulfur is provided through a persulfide intermediate
by a pyridoxal phosphate-dependent cysteine desulfurase, IscS in
bacteria and the Nfs1/Isd11 complex in eukaryotes, that interacts
with the scaffold protein to form a complex in which Fe-S cluster
biosynthesiswasproposedtooccurinvivo[19].Theexactfunctionof
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stabilize Nfs1 through a direct interaction [20,21]. The bacterial,
yeast and human frataxins (CyaY, Yfh1 and FXN, respectively)
were shown to interact with multiple core components of the
biosynthesis machinery [11–16]. Furthermore, in vitro, iron loaded
human frataxin was shown to deliver iron to ISCU [6]. However,
howfrataxininteractswith the Fe-Sclusterbiosynthesiscomponents
remains unclear as direct one-to-one interactions with each
component were reported (IscS [12,22], IscU/Isu1 [6,11,16] or
ISD11/Isd11 [14,15]). Finally, the iron-donor function of frataxin
has recently been challenged as in vitro kinetic studies of Fe-S cluster
biosynthesis using the bacterial components revealed that CyaY
behaves as an iron-dependent inhibitor of Fe-S cluster assembly
through a specific interaction with IscS [22]. Additional experi-
ments are thus required to clarify both the function(s) and the
molecular network(s) of the frataxin protein.
To obtain a comprehensive insight into the multiple functions of
frataxin, we decided to identify and characterize the interactions of
human frataxin. In the present work, we show that endogenous
mitochondrial ISCU, NFS1, and ISD11 are the main interactors
of frataxin. Using complementary in vitro and in vivo experiments,
we infer that the essential function of mammalian frataxin consists
in interacting with the preformed ISCU/NFS1/ISD11 complex,
forming a <190 kDa quaternary complex that can be isolated in a
stable form. Finally, we demonstrate that the function of frataxin is
sustained in vivo by the mature and monomeric form of frataxin.
Results
The Fe-S cluster biosynthesis machinery components
NFS1, ISCU and ISD11 are the main interactors of mature
frataxin
We searched for the interacting partners of human frataxin by
coupling immunoprecipitation (IP) with mass spectrometry
analysis. Due to competition between the immunoprecipitating
1G2 antibody and interactors, IP of endogenous frataxin failed to
identify protein partners (data not shown), with the exception of
the mitochondrial processing peptidase (MPPb) involved in the
maturation of frataxin [23]. Therefore, IP was performed from
HeLa mitochondrial extracts expressing a recombinant human
frataxin with a C-terminal flag epitope (hFXN-Flag). As reported,
three forms of frataxin, the precursor (25 kDa), the intermediate
(19kDa) and the mature (14 kDa) forms [24] were specifically
immunoprecipitated from the corresponding HeLa mitochondrial
fractions using an anti-Flag antibody (data not shown). Mass
spectrometry analysis identified only four common proteins
(ISCU, NFS1, ISD11 and MPPb) from two independent
experiments that specifically co-immunoprecipitated with hFXN-
Flag, with an average coverage ranging from 3–61% (Fig 1A and
Table S1). The four proteins were not detected in the negative
control in contrast to the mitochondrial HSPA9 and HSPD1
chaperones (Table S1). The specific interaction with endogenous
ISCU and NFS1 was confirmed by western blot analysis (Fig 1B).
Unfortunately, the available ISD11 antibody did not detect the
endogenous ISD11 from mitochondrial HeLa cell extract.
To further confirm these interactions, we performed GST pull-
down experiments from HeLa mitochondrial extracts using the
mature form of human frataxin (aa 81–210) fused to an N-terminal
GST (GST-hFXN81–210). A specific interaction between frataxin
and endogenous ISCU and NFS1 was detected by western blot
(Fig 1C), in agreement with the IP experiments. Interestingly, the
addition of the 1G2 monoclonal antibody, which recognizes an
epitope located in the sequence encoded by exon 4 of frataxin,
completely abolished the interaction with ISCU and NFS1 (Fig
S1A), suggesting a role of this conserved region in the interaction.
No difference in interaction with ISCU and NFS1 was detected
with the intermediate (GST-hFXN42–210) and mature (GST-
hFXN81–210) forms of frataxin in GST-pull down experiments (Fig
S1B), indicating that the site of interaction with the complex is
fully comprised within the sequence of the mature form.
Therefore, all further experiments were performed with the
recombinant mature form of frataxin.
Interestingly, mitochondrial aconitase or ferrochelatase were
not detected in the IP and the GST pull-down eluates, despite de
presence of both proteins in the soluble input fraction (Fig 1B and
1C). As the interaction between frataxin and mitochondrial
aconitase was shown to be promoted by hydrogen peroxide/
citrate treatments [10], IP experiments were carried out under
these prooxidant conditions. Whether hFXN-Flag or endogenous
mitochondrial aconitase were used as bait for IP, no interaction
between frataxin and aconitase was observed (Fig S2).
Our results clearly show that the main interactors from
mitochondrial HeLa cell extract of a C-terminal or N-terminal
tagged human mature frataxin (hFXN81–210) are the core
components of the de novo Fe-S cluster biosynthesis, ISCU, NFS1
and ISD11.
Frataxin interacts with a preformed ISCU/NFS1/ISD11
complex
To determine which component of the ISCU/NFS1/ISD11
complex is the direct partner of frataxin, we co-expressed the mature
form of the murine homologues in multiple combinations in the
bacteria, followed by GST purification. For all bacterial expressed
recombinant proteins (GST or His-tagged), the mitochondrial
targeting sequence was removed from FXN, NFS1 and ISCU.
Each construct expressed soluble protein in bacteria when expressed
alone or in combination (Fig S3A). When GST-mFXN was co-
expressed either with mISCU alone or with mNFS1/mISD11 or
mNFS1/mISCU, no co-purification was detected (Fig 2A). It is only
when GST-mFXN, mISCU, mNFS1 and mISD11 were co-
expressed that a co-purification of all four proteins was observed
(Fig 2A). These results demonstrate that frataxin is able to interact
with co-expressed ISCU, NFS, ISD11 proteins and suggest that
frataxin interacts with a ISCU/NFS1/ISD11 complex rather than
with individual components. As mNFS1/mISD11 are the limiting
factors due to lower expression and insolubilityinbacteria compared
to GST-mFXN and mISCU (data not shown), little complex was
purified compared to the large excess of GST-mFXN. However,
when a limiting amount of purified GST-mFXN was used to pull-
down the complex from a bacterial extract expressing mISCU/
mNFS1/mISD11, the quaternary complex could be isolated at
nearly stoichiometric levels (Fig S3B). In the absence of mISD11,
neither the quaternary nor the ternary complex formed (Fig. 2A),
further suggesting that ISD11 is important for NFS1 stability.
Native PAGE analysis of both bacterial co-purification (Fig 2B)
and GST-hFXN pull-down eluates obtained with endogenous
ISCU,NFS1andISD11fromHeLamitochondrialextracts(Fig2C)
revealed the presence of one major complex containing only the
four proteins as verified by mass spectrometry (Fig. 2C) and western
blot (data not shown), further demonstrating the presence of a
quaternary complex. The identification of endogenously expressed
ISD11 in the native complex further confirmed the original co-IP
experiments. When isolated from bacterial co-expression, the
quaternary complex could be easily concentrated to 5mg/ml,
without precipitation.
While frataxin only interacts in a quaternary complex, the
ternary complex mISCU/mNFS1/mISD11 could be isolated in
the absence of frataxin. Indeed, when mISCU-HIS, mNFS1 and
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mISCU-HIS (Fig 2D). Furthermore, pull-down experiments using
GST-mFXN as a bait demonstrated an interaction between GST-
mFXN and the pre-purified mISCU-HIS/mNFS1/mISD11
complex (Fig 2D). In contrast to the quaternary complex, the
ternary mISCU/mNFS1/mISD11 complex was susceptible to
aggregation upon concentration.
Contrary to the reported data in yeast demonstrating that iron
reversibly increase the binding of Yfh1 to Isu1/Nfs1 [11], under
similar experimental conditions, we did not observe any increase
nor decrease of FXN binding to the core complex (Fig S4A–B).
Furthermore, high (100mM) or low (using bathophenanthroline
Fe
2+ chelation) iron concentrations in reducing condition, or the
presence of different metals (50 mMC a
2+,N i
2+,Z n
2+,M g
2+) had
no effect on the formation of the complex (Fig S4C–D).
Together, our results demonstrate that frataxin interacts with a
preformed ISCU/NFS1/ISD11 complex rather than with the
individual components to form a stable quaternary complex.
A surface encompassing the acidic ridge and the b-
sheets is involved in the interaction between frataxin and
the core complex
To identify residues on frataxin that are essential for the
interaction with the ISCU/NFS1/ISD11 complex, 13 recombi-
nant GST-tagged human mature FXN81–210 carrying specific
point mutations were tested by GST pull-down using mitochon-
drial HeLa cell extracts (Fig 3A–B). Again, only endogenous ISCU
and NFS1 could be detected by western blot due to the inability of
the ISD11 antibody to detect endogenous ISD11. Six of the
mutational substitutions constructed are pathological mutations
found in compound heterozygous FRDA patients (D122Y,
G130V, N146K, I154F, W155R and W173G) [25]. Seven
mutations were directed against acidic residues from the acidic
ridge of frataxin (E96K, D104G, E108K, E111K, D115K, D122Y
and D124K). One mutation, Y95G, was proposed to stabilize the
trimeric structure in yeast frataxin [26]. All mutations involved
residues exposed on the protein surface except Y95, I154 and
W173, for which side chains are mostly buried in the protein core
(Fig 3B). Therefore, the absence of interaction of the W173G
recombinant protein and the reduced interactions of the Y95G
and I154F recombinant proteins most likely reflect a structural
role of these residues (Fig 3A). These results are consistent with
several studies that have reported the effect of the W173G and
I154F mutations on the stability of the human frataxin protein,
both in vitro and in vivo [15,27–29]. While the E108K and E111K
mutants enabled the interaction with the complex, although
diminished, the D124K mutation caused a drastic decrease in the
interaction with ISCU and NFS1 (Fig 3A). Mutations at the acidic
Figure 1. Human frataxin interacts specifically with ISCU, NFS1 and ISD11. (A) Mass spectrometry analysis of proteins identified by co-IP
with FLAG-tagged frataxin from HeLa mitochondrial enriched fractions. Results represent the proteins specifically identified common to two
independent experiments with hFXN-FLAG expressing cells compared to non-transfected cells. Peptides were selected with a stringent filter to avoid
a maximum of false positives. Coverage represents the percentage of sequence matching with peptides found in the analysis. An example of
complete results for one experiment is given in Table S1. (B) IP obtained in (A) were analyzed by Western blot using specific antibodies against
frataxin (intermediate and mature), mitochondrial aconitase (mACO), NFS1, ferrochelatase (FECH), MnSOD and ISCU. MnSOD was used as a control to
evaluate non-specific binding on the beads. Inputs correspond to 5mg of mitochondrial HeLa extracts. (C) GST pull-down using GST-hFXN (aa 81–210)
and HeLa mitochondrial extracts. Eluted fractions were analyzed by Western blot as in (B) or by coomassie blue staining to detect GST and GST-hFXN.
doi:10.1371/journal.pone.0016199.g001
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G130V mutation, associated with an atypical milder phenotype in
FRDA, had no impact on the interaction (Fig 3A). In contrast, the
W155R and the N146K mutations strongly affected the
interaction with NFS1 and ISCU (Fig 3A). Similarly, ISCU,
NFS1 and ISD11 were not detected by mass spectrometry analysis
(Table S1) or western blot in a FXN
N146K-flag IP from HeLa
mitochondrial extract, although MPPb was detected (data not
Figure 2. Frataxin binds a pre-formed ISCU/NFS1/ISD11 complex. (A) Co-purification of ISCU/NFS1/ISD11 with GST-mFXN. GST-mFXN or GST
were co-expressed with mISCU, mNFS1/mISD11 or mISCU/mNFS1/mISD11 in bacteria (+ and 2 indicates the presence of each expressing vector).
Fractions were analysed by SDS-PAGE and coomassie blue staining (upper panel) or by Western blot (IB). (B) GST-mFXN was co-expressed with
mISCU, mNFS1 and mISD11 and purified as in (A). Samples were loaded on a 7.5% non-denaturing gel and stained with coomassie blue. Western blot
analysis and mass spectrometry analysis confirmed that the upper band corresponds to a complex containing mFXN, mISCU, mNFS1 and mISD11. (C)
Co-purification of NFS1/ISD11 with mISCU-HIS (left). mISCU-HIS was co-expressed with mNFS1 and mISD11 and purified by cobalt column. Co-
purification of mISCU-HIS/mNFS1/mISD11 with GST-mFXN (right). GST pull down using GST or GST-mFXN with purified mISCU-HIS/mNFS1/mISD11
complex. The samples were loaded on a SDS-gel and analysed by Western blot using NFS1, ISD11 and ISCU specific antibodies. + and 2 indicate the
presence and the absence of the corresponding vectors, respectively. (D) Native complex from HeLa cells. GST and GST-hFXN were incubated with
mitochondrial HeLa extract, pull-down and loaded on non-denaturing gel. Only two protein complexes were detected by coomassie staining. Mass
spectrometry analysis and western blot confirmed that one corresponds to GST-hFXN dimer and the second to the GST-hFXN/ISCU/NFS1/ISD11
complex. With the exception of the common contaminating proteins (keratins and elongation factor 1) found by mass spectrometry analysis, the only
proteins present in the band corresponding to the quaternary complex were NFS1 (10 peptides, 28.2% coverage), hFXN (5 peptides, 18.6% coverage),
ISCU (4 peptides, 24% coverage) and ISD11 (4 peptides, 29.7% coverage).
doi:10.1371/journal.pone.0016199.g002
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mISD11 could be observed using GST-hFXN
N146K in a bacterial
co-expression experiment (Fig S3C).
As the absence of interaction with the N146K and W155R
mutants could be due to steric or electrostatic hindrance, two
milder mutations were constructed, replacing N146 and W155 by
alanines. The N146A mutation restored the interaction with the
complex, while the W155A mutation did not (Fig 3C), indicating
that the protruding tryptophan is an essential residue for
interaction with the complex.
We have therefore identified three mutations directed against
the residues from the acidic ridge of frataxin (E108K, E111K and
D124K) and two surface-exposed mutations (W155R and N146K)
that specifically disrupted the interaction of frataxin with the core
complex, defining a surface of interaction on one side of frataxin,
spreading from the acidic ridge to the b4-sheet (Fig 3D).
The association of frataxin with the de novo Fe-S cluster
biosynthesis complex is crucial for cellular function
To determine whether the interaction between frataxin and the
core complex is an essential function of frataxin in vivo,w e
generated four murine fibroblast cell lines stably expressing full
length hFXN
N146K, hFXN
N146A, hFXN
W155R or hFXN
W155A in
the conditional allele background enabling the deletion of the
endogenous gene [30]. Complete frataxin deficiency in this
fibroblast cell line does not sustain cell division and survival
[30]. All mutant proteins were properly targeted to mitochondria
and matured (Fig S5A). After endogenous frataxin deletion, while
we isolated 12 clones carrying wild-type frataxin, 5 clones
expressing the hFXN
N146A, and a single clone expressing the
hFXN
N146K (Fig 4A), no clone expressing either hFXN
W155R or
hFXN
W155A was isolated (Fig S5B–C), further demonstrating that
W155 is an essential residue for frataxin function. Wild-type and
N146A clones did not present any gross phenotype (Fig 4B), nor
sensitivity to oxidative stress (Fig S5C–D), a feature of frataxin
haploinsufficiency [30]. In contrast, the N146K clone showed
spindle-shaped and retracted cells with a strong growth defect, and
displayed the classical features of FRDA (degenerating mitochon-
dria, electron dense deposits, deficit in Fe-S enzyme activities)
(Fig 4B–C and Fig S5E). Together, these results strongly suggest
that interfering with the quaternary complex formation in the cell
leads to a typical FRDA phenotype and that the interaction of
frataxin with the core complex is the essential function of
mammalian frataxin in vivo.
The quaternary complex has a molecular mass of
<190 kDa
Two different strategies were followed to purify the quaternary
complex. Either a double GSH and nickel column purification or
a single nickel column purification was carried out from GST-
mFXN/mISCU/HIS-mNFS1/mISD11 or mFXN-HIS/mISCU/
mNFS1/mISD11 expressing bacteria, respectively (Fig S6A). The
complexes were further purified by gel filtration. Fractions
containing the GST-mFXN/mISCU/HIS-mNFS1/mISD11 com-
plex (fractions 14 to 18 corresponding to <4 mg of complex, Fig.
S6B) or the mFXN-HIS/mISCU/mNFS1/mISD11 (fractions 19
and 20 corresponding to <3 mg of complex, Fig. 5A) were
concentrated for native ESI mass spectrometry analysis. Multi-
Figure 3. Residues in the aa1-helix and the b-sheets of frataxin are crucial for the interaction with ISCU and NFS1. (A) GST pull-down
using different GST-hFXN mutants. GST-hFXN mutants were obtained by directed mutagenesis (only amino acid changes are indicated). GST pull-
downs were carried out as in Fig 1C and analyzed by SDS-PAGE and coomassie blue staining to visualize GST-hFXN (upper panel), and by Western
blot using antidodies against NFS1 and ISCU. (B) Solution structure of human frataxin (PDB ID 1LY7) showing the localization of the residues mutated.
(C) GST pull-down using GST-hFXN mutants N146K, N146A, W155R and W155A. Experiments were carried out as in Fig 1C. (D) Top view of the
solution structure shown in (B). The five residues affecting the interaction with the ISCU/NFS1/ISD11 complex define a potential interaction surface on
frataxin.
doi:10.1371/journal.pone.0016199.g003
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of mitochondria-enriched fractions from clones expressing wild type frataxin, mito81–210, FXN
N146A and FXN
N146K using anti-frataxin and anti-tubulin
antibodies. (B) Morphological and ultrastructural alterations in FXN, N146A, N146K and mito81–210 clones. Each clone was studied by phase contrast
microscopy after crystal violet staining (left panels) and electron microscopy analysis (right panels). mt, mitochondria; Lp, lipid droplet; mt-Fe,
intramitochondrial iron deposits; N, nucleus. (C) Biochemical measurements of Fe-S enzyme activities in FXN, N146A, N146K and mito81–210 clones.
Succinate dehydrogenase (grey bars) and aconitases (dark grey bars) specific activities were standardized to isocitrate dehydrogenase (IDH) specific
activity and expressed as percentage of control activity. Results were obtained from two independent experiments using 4 FXN, 3 N146A, 1 N146K
and 4 mito81–210 clones. Data are represented as mean + SD. * p,0.05.
doi:10.1371/journal.pone.0016199.g004
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potential (250 kV) (Fig 5B and Fig S6C). Molecular weights of
237,130 Da and 189,623 Da were deduced for the GST- mFXN/
mISCU/HIS-mNFS1/mISD11 and mFXN-HIS/mISCU/mNFS1/
mISD11 complexes, respectively. The difference between the
masses of the two complexes is suggestive of two frataxins per com-
plex, considering the difference in mass between GST-mFXN and
mFXN-HIS (Fig S6D). Furthermore, using a concentration curve of
purified proteins, the mISCU:mFXN ratio per complex was
estimated to be one (Fig S6E). Such calculation could however
not be achieved for mNFS1 or mISD11, as neither protein is
stable when expressed alone. Although the ternary complex can
be isolated by gel filtration (Fig S7A), the yield is very low due to
instability of the complex upon concentration. As for the bacte-
rial IscU/IscS complex [19], the ternary complex can be
stabilized by the insertion of the D72A mutation on mISCU
(Fig S7B). However, this stabilization is not sufficient to allow
concentration for ESI mass spectrometry analysis. Therefore,
assuming mNFS1 as a dimer, the observed mass is suggestive of
stoichiometric amount of mNFS1, mFXN and mISCU. Interest-
ingly, the mass is compatible with the presence of 3 or 4 mISD11
per complex (Fig. S6D).
The mitochondrial hFXN81–210 form of frataxin is the
essential functional form in vivo
Mature hFXN81–210 is the main endogenous form of frataxin in
human tissues and cell lines [24]. However, during the maturation
process, a longer intermediate form (hFXN42–210) is expressed.
This intermediate form, as well as a longer hFXN56–210 form can
interact with the core complex (Fig S1B). To determine whether
hFXN81–210 is the essential functional form of frataxin in vivo,w e
expressed a recombinant protein (mito81–210) with its own
mitochondrial targeting sequence (aa 1–41) fused directly to the
sequence of mature frataxin (aa 81–210), bypassing the interme-
diate hFXN42–210 form. Interestingly, when expressed in Cos-1
cells, although mito81–210 was correctly processed, the level of
mature frataxin was decreased, and the precursor form accumu-
lated within the cytosol (Fig S5F), suggesting that amino acids 42–
80 of human frataxin are partially involved in the mitochondrial
targeting. In murine fibroblasts, mito81–210 was able to completely
Figure 5. Determination of the molecular weight of the FXN/ISCU/NFS1/ISD11 complex. (A) Gel filtration for the mFXN-HIS/mISCU/
mNFS1/mISD11 complex. After a single nickel column purification, the sample was loaded and separated by gel filtration. Coomassie staining of a
denaturing and a non-denaturing gel corresponding to fractions 2 to 40 are shown. Fractions 19 and 20 that contained the complex were
concentrated for the native mass spectrometry analysis. (B) ESI native mass spectra of the mFXN-HIS/mISCU/mNFS1/mISD11 complex after gel
filtration purification. The experimental molecular weight for each component was 10,722 Da, 14,543 Da, 15,333 Da and 44,669 Da for mISD11,
mISCU, mFXN-HIS and mNFS1, respectively. The mass was estimated to the molecular weights of 189,623 Da.
doi:10.1371/journal.pone.0016199.g005
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whereas a cytosolic version of hFXN81–210 was unable (Fig 4 and
Fig S5B–C). The clones expressing mito81–210 showed no
morphological or structural abnormalities (Fig 4B), normal Fe-S
enzyme activities (Fig 4C), and no susceptibility to exogenous
oxidative stress (Fig S5D). These results demonstrate that mito81–
210 is sufficient to complement endogenous frataxin functions and
promote survival, providing the evidence that mature hFXN81–210
is the functional form for in vivo Fe-S cluster biosynthesis.
Discussion
Frataxin has been proposed to be a multifunctional protein
based on its numerous interactions, including components of the
Fe-S biosynthesis machinery, ferrochelatase, mitochondrial acon-
itase, succinate dehydrogenase, and several chaperones [2,9–
12,15]. In the present study, the only endogenous proteins that co-
purified with a recombinantly expressed frataxin are ISCU, NFS1,
ISD11 and MPPb, suggesting that these proteins stably associate
with frataxin, and belong thus to the core network of frataxin
partners in vivo. Furthermore, we showed that in vivo expression of
frataxin mutants that affect the interaction with the core
components of de novo Fe-S cluster biosynthesis triggers cell death
(W155R and W155A) or a classical FRDA phenotype (N146K),
while frataxin mutants that keep the ability to interact lead to
normal cellular phenotype (N146A). Altogether, our results
strongly suggest that the interaction of frataxin with the Fe-S
cluster assembly complex defines the essential function of frataxin
in vivo. Although the relevance of the other reported interactions
needs to be further investigated in vivo, we cannot exclude that less
stable or transient interactions with frataxin could not be detected
in our experimental conditions. Furthermore, we show that
mitochondrial mature frataxin (hFXN81–210) was sufficient to
support cell survival with a normal phenotype (Fig 4).
Eachof the individualcomponents ofthede novo Fe-S biosynthesis
complex (Isu/Iscu, IscS and Isd11) has been proposed to be the
molecular adaptor for frataxin interaction [6,11,12,14,15,22].
However, in the heterologous expression system, our results
demonstrate that mammalian frataxin interacts with the preformed
ISCU/NFS1/ISD11 complex rather than with the individual
proteins. The interaction of frataxin in complex with both the Fe-S
scaffold and the cysteine desulfurase is most likely conserved
throughout evolution, as demonstrated by the co-purification of
Isu/Nfs1 with Yfh1 in yeast [11] and IscU/IscS with CyaY in
bacteria [12]. However, in contrast to our results with the
mammalian protein, in yeast, a N122K mutation on Yfh1
(equivalent to the human N146K) had more effect on the
interaction with Isu1 than with Nfs1/Ids11 [16], indicating that
thisresidueismostlikelyinvolved inthe interactionwith thescaffold
protein. In addition, mutations on positively charged residues of
IscS were recently reported to affect specifically the interaction of
IscS with CyaY [31]. Similarly, mutations on positively charged
residues of Nfs1 perturbed the complex formation in the
mammalian system (Fig S3D). Together with our results, these
data strongly suggest that NFS1 and ISCU define the interaction
surface that is targeted by frataxin. Based on the mutational screen
results and the published literature [13,15,16,22,31], we propose
that part of the acidic ridge of frataxin could be involved in the
interaction withconserved basic residues of NFS1, whileresidues on
the b-sheets (including W155) would be crucial for the interaction
with ISCU. Although p interactions between the W155 and R165
residues contribute to frataxin stability [28], it is unlikely that a fold
defect of the W155A mutant underlies the loss of interaction with
the complex, as the protein was properly expressed and matured in
vivo, and was not degraded by the mitochondrial quality control
protease machinery. Furthermore, in Yfh1, a R141A mutation
which should elicit the loss of the p interactions between W131 and
R141, had no effect on the interaction with Isu1 [13]. Finally, the
crystal structure of the bacterial IscS/IscU complex demonstrated
one IscU monomer per active site of IscS, which are located on
opposite sides of the IscS homodimer [31]. Based on the
stoichiometry and the mutagenesis experiments, it is reasonable to
hypothesize that there is one FXN monomer and one ISCU
monomer per active site of NFS1. Furthermore, the mass
spectrometry data suggest that there are 3–4 ISD11 on the
complex. While the exact role of the eukaryotic ISD11 is not
known, it is clearly essential for both the quaternary and ternary
complexes formation (Fig 2A). Whether frataxin and ISD11 have
direct interacting surfaces still needs to be determined.
It has recently been suggested that iron oxidation-driven
oligomerization of yeast frataxin promotes the assembly of a
stable core Fe-S complex [14]. Our data clearly demonstrate that
the mature hFXN81–210 is the essential form of frataxin in vivo.
While we have not directly tested the capacity of hFXN81–210 to
oligomerise, it has recently been reported that hFXN81–210 is not
prone to iron-induced oligomerisation [32], in contrast to yeast or
bacterial frataxin or longer forms of human frataxin. Furthermore,
our native gel analyses as well as our gel filtration and
stoichiometric data are incompatible with an oligomeric form of
frataxin as the functional unit in the purified quaternary complex.
Finally, it is worth noting that the sites of interaction with the
complex that we have identified on frataxin are buried within the
oligomeric structure [26]. Together, these results are not
supportive of an oligomeric form of frataxin as the essential
functional unit in vivo for Fe-S cluster biosynthesis, but rather
suggest that mature frataxin is monomeric.
Frataxin has been proposed to be either the iron donor for Fe-S
cluster biosynthesis or a regulatory protein that inhibits Fe-S
cluster formation [11,22]. Although we cannot conclude on the
role of frataxin as the iron donor for Fe-S cluster assembly, our
experiments indicate that the iron concentration does not
modulate the interaction between mammalian frataxin and the
ternary complex. While the reason for this observed difference
with the yeast remains to be determined, it might arise from the
relatively different iron-binding properties of mammalian frataxin
in comparison to yeast frataxin [3]. Furthermore, in vivo frataxin
deficiency [33,34,35] as well as the expression of the N146K
mutant (Fig 4C) lead to a strong decrease of Fe-S cluster
biosynthesis rather than a complete deficit. These data demon-
strate that frataxin is required but not essential for proper Fe-S
cluster biosynthesis, and suggest that frataxin might facilitate
efficient Fe-S cluster biosynthesis in vivo. In bacteria, cluster
assembly has been demonstrated to be a dynamic process that
involves the dissociation of IscU and IscS for cluster transfer [19].
By interacting with a preformed ISCU/NFS1/ISD11, FXN
probably prevents the dissociation of NFS1/ISD11 and ISCU,
having the effect of increasing the stability of the ISCU/NFS1/
ISD11 interaction. To quantitatively demonstrate the effect of
frataxin on the stability of the ternary complex, the affinities of
ISCU for NFS1/ISD11 in the absence and the presence of
frataxin should be measured. However, the current technical
difficulties to purify large quantities of the mammalian NFS1/
ISD11 complex prevent such an approach. Assuming that, as
mammalian frataxin, CyaY preferentially interacts with the
preformed IscU/IscS complex, the addition of frataxin in
reconstitution experiments would lead to uncompetitive inhibition,
thus explaining the reported inhibitory effect of CyaY on Fe-S
cluster formation in vitro [22].
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the core complex in the heterologous system open new
perspectives on how frataxin might facilitate Fe-S cluster
biogenesis in vivo. While in the absence of frataxin, the interaction
between ISCU and NFS1/ISD11 is unstable and very dynamic
[19], frataxin might function by maintaining the ISCU/NFS1/
ISD11 interaction. Interestingly, a recent crystal structure of the
bacterial IscS/IscU heterotetramer demonstrated that the catalytic
cysteine of IscS and the acceptor cysteines on IscU are too far in
distance to allow direct transfer, suggesting that a conformational
rearrangement is necessary to bring together the sulfur donor and
the acceptor cysteines [31]. It is tempting to speculate that frataxin
interaction with the complex triggers this conformational rear-
rangement to allow efficient sulfur and iron transfer. By analogy to
Thermus Thermophilus Nqo15, the frataxin-like subunit present in the
hydrophilic domain of the respiratory chain complex I [36], one
possibility would be that frataxin creates a channel on the interface
with the complex allowing a more efficient iron delivery into the
site of cluster synthesis. It has recently been proposed, based on
biochemical and biophysical data, that the Isu1-interacting surface
of yeast frataxin encompasses the iron binding sites, thereby
positioning frataxin for iron delivery to Isu1 close to the Fe-S
cluster assembly site [37]. The authors suggest a model in which
frataxin would dissociate from the complex following iron delivery,
prompting Isu1 to complete Fe-S cluster assembly [37]. On the
other hand, a stabilised complex might be necessary to provide a
safe environment for Fe-S cluster formation or to allow all the
consecutive reaction steps to occur. Further challenging biochem-
ical and spectroscopic studies are necessary to characterize the role
of frataxin within the quaternary complex, as well as the sequence
of events of the early steps of de novo Fe-S cluster biogenesis.
While our manuscript was under review, two groups indepen-
dently reported biochemical results that nicely complement our
work [38,39]. Similarly to our results, Tsai et al. provided in vitro
evidence that human frataxin binds, in an iron independent
manner, to a NFS1, ISCU and ISD11 complex to generate the
quaternary complex [38]. Very interestingly, they demonstrated
that frataxin stimulates the cysteine desulfurase activity. As the
cysteine desulfurase activity could be further stimulated by the
additon of Fe
2+, the authors proposed that frataxin functions with
Fe
2+ as an allosteric activator for Fe-S cluster assembly. In the
second manuscript, by combining small-angle X-ray scattering
(SAXS) and NMR studies with mutagenesis studies on the
bacterial homologs, Prischi et al. have defined an interaction
surface between CyaY, IscS and IscU that is consistent with the
interaction surface that we have proposed [39]. Furthermore,
through biolayer interferometry, they demonstrated that CyaY
enhances the affinity of IscU on IscS, thereby stabilizing the
complex, providing the biophysical evidence for the inhibitory
effect of CyaY on IscS/IscU enzymatic kinetics. In the future, it
will be extremely interesting to further compare the biophysical
characteristics of the complexes from different organisms and to
determine the effect of the pathological FRDA mutations on the
cysteine desulfurase activity and Fe-S cluster assembly.
Materials and Methods
Recombinant protein purification
The technical procedures involved in plasmid and strain
constructions are described in Material and Methods S1. For
low scale GST purifications, the suspension was centrifuged
15,000 g, 4uC for 15–30 min and the supernatant was incubated
with glutathione-S-sepharose beads (Pharmacia) for 3 hours at
4uC. The mix was loaded on chromatography column (BIORAD)
and washed with PBS. Elution was performed with 35mM
glutathione in Tris-HCl 100mM, pH 8, NaCl 150mM for 10 min
at 4uC. Elutions were dialysed 2–3 hours in PBS, 5mM EDTA,
5mM DTT at 4uC using dialysis column (ThermoScientific). For
large-scale purification, the suspension was centrifuged
40,000 rpm (Ti50.2, Beckman), 4uC, 30 min and the supernatant
was further purified by FPLC (AKTA, GE Healthcare). The
supernatant was loaded on Cobalt or Nickel affinity column (GE
Healthcare) or glutathione sepharose affinity column (GE
Healthcare). After wash with PBS, elution was carried out using
200mM imidazole or 35mM glutathione. Gel filtration (GF) was
carried out on Superdex S200 (16/90) or (10/30) (Amersham
Biosciences) columns. For native mass spectrometry analysis,
elution was performed with 50mM ammonium acetate. Samples
were concentrated using Vivaspin columns (c.o. 100,000, Sarto-
rius). Protein concentrations were determined by Bradford assay.
GST pull-down assays
GST pull-downs were performed by incubating 100mg of GST-
fused protein with 5–10mg mitochondria enriched extracts and
glutathione-S sepharose beads for 3 hours in Tris-HCl 100mM,
pH 7.5, 10% glycerol, 100mM KCl and Complete protease
inhibitor cocktail (Roche). The mix was loaded on a chromatog-
raphy column (BIORAD), washed with PBS, 100mM KCl.
Elution was performed in loading buffer after boiling for
10 min. To test the effect of metals on the interactions, 50mMo r
100mM FeSO4 with 500mM-10mM ascorbic acid or 50 mMo f
either NiSO4, MgSO4, CaCl2 or ZnCl2 were added during
extraction and wash steps. Iron chelators (EDTA or bath-
ophenanthroline disulfonic acid) 1mM were added in some
samples during wash or incubation steps, as indicated in figure
legends.
Cell culture and protein extraction
HeLa cells (ATCC-USA) were grown and transfected as
previously described [24]. Cells were harvested 24 hours after
transfection. Culture, stable transfection, and clonal selection of
immortalized mouse fibroblasts established from Frda
L3/L2 mice
were carried out as described [30]. Total, mitochondrial-enriched
and cytosolic fractions were obtained as described [24].
Biochemical assays
Enzymatic activities, crystal violet staining, electron microscopy
and determination of the sensitivity to stress were performed as
previously described [30].
Immunoprecipitation
FLAG-tagged proteins were immunoprecipitated by incubating
overnight 100–200mL FLAG M2 coupled resin (SIGMA) (pre-
pared as recommended by the manufacturer) with 500mg to 1.5mg
of mitochondria enriched extract in Tris-HCl 100mM, pH 7.5,
10% glycerol, 100mM KCl and Complete protease inhibitor
cocktail (Roche). The mix was loaded on a chromatography
column (BIORAD), washed 4 times with 5 mL PBS, 100mM KCl.
Elution was performed by resuspending the beads in loading
buffer and boiling for 10 min or by incubating beads with glycine
0.1 M pH 3 for 10 min. IP of endogenous mitochondrial
aconitase was performed as described [10].
PAGE and Western blot analysis
14% acrylamide SDS-Glycine-PAGE was used unless otherwise
indicated. 7.5% or 10% acrylamide native gels were prepared
without reductant. Western blot were carried out as previously
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and Methods S1. Silver staining was performed as described [24].
Quantification of coomassie blue staining was performed on a
Chemigenius
2 (SYNGENE).
Mass spectrometry analysis
IP were loaded on 4–12% NuPAGEH gel (INVITROGEN).
Ten bands from 5 kDa to 130 kDa were cut and prepared for MS
analysis using trypsin for the protein digestion. Samples were
analysed by NanoLC-nanoESI/MS
2. Native mass determination
was carried out by ESI-MS analysis. Further details are given in
Material and Methods S1.
Statistics
All data represent mean 6 SD. The statistical analysis was
performed by standard Student T-test. Statistical significance was
considered at p,0.05.
Supporting Information
Figure S1 Conserved domain of frataxin is involved in
the interaction with ISCU and NFS1. (A) The monoclonal
1G2 antibody directed against exon 3–4 of frataxin prevented the
interaction between frataxin and ISCU and NFS1. GST pull-
down was performed as described in Fig. 1C with the addition (+)
or not (2) of 1G2 antibody. Note that the 1G2 antibody is retained
by GST-hFXN (heavy and light chain) and prevents interaction
with ISCU and NFS1. (B) GST-hFXN pull-down was performed
on mitochondrial Hela extract as in Fig. 1C using different GST-
hFXN constructs. As the capacity of GST-hFXN42–210, GST-
hFXN56–210 and GST- hFXN81–210 to interact with NFS1 and
ISCU were equivalent, we perform all following GST pull-down
with the GST-hFXN81–210 expressing construct that corresponds
to the size of the endogenous mature human frataxin.
(JPG)
Figure S2 Absence of interaction between frataxin and
mitochondrial aconitase. (A) Immunoprecipitation of mito-
chondrial aconitase from HeLa mitochondrial extracts was
performed exactly as described (1), with the same anti-aconitase
antibody kindly provided by Anne-Laure Bulteau. Mitochondria
were treated with 100 mM hydrogen peroxide and 2 mM of citrate
(+) prior to the IP. Samples were loaded on SDS-PAGE and
analysed by Western blot using specific antibodies against frataxin
and mitochondrial aconitase. (B) Immunoprecipitation of hFXN-
FLAG was performed as in Fig. 1A. Mitochondria were treated or
not with hydrogen peroxide and citrate as in (A). Samples were
analysed by Western blot.
(JPG)
Figure S3 Frataxin interaction with ISCU/NFS1/ISD11
complex and effects of mutations. (A) Expression of mNFS1,
mISCU and mISD11 in bacteria co-transformed with different
sets of vectors. Soluble fractions of bacteria expressing GST-FXN,
mNFS1, mISD11 and/or mISCU were loaded on a SDS-gel and
analysed by Western blot using NFS1, ISD11 and ISCU specific
antibodies. + and 2 indicate the presence and the absence of the
corresponding vectors, respectively. (B) GST pull-down using a
limiting amount of GST-FXN and a bacterial extract expressing
mISCU/mNFS1/mISD11. 25mg of GST or GST-FXN were
added to the bacterial lysate before purification on glutathione-
sepharose beads. The elutions were analyzed on SDS-PAGE by
silver staining. (C) Co-purification of ISCU/NFS1/ISD11 with
GST-hFXN
N146K. GST-hFXN or GST-hFXN
N146K (N146K)
were co-expressed with mISCU, mNFS1 and mISD11 and
purified on glutathione-S-sepharose column as in Fig. 2A. Elutions
were analysed by SDS-PAGE and coomassie blue staining (upper
panel) or Western blot (IB). (D) Mutations of positively charged
residues on NFS1 affect frataxin interaction with the complex.
R220D and R225D mutations were introduced by directed
mutagenesis on mNFS1 cDNA. Co-purification was carried out
as in Fig. 2A and analyzed on native and denaturing gel by
coomassie blue staining. Western blot on mNFS1 was performed
to verify the correct expression of the two mNFS1 mutants.
(JPG)
Figure S4 Absence of effect of different metals on
complex formation. (A) Effect of iron on the interaction of
frataxin with ISCU and NFS1. GST pull-down was carried out as
in Fig. 1C with the exception that the extraction, purification and
wash steps were carried out in the absence or the presence of
100 mM FeSO4/1 mM ascorbate (Fe
2+) and 1 mM EDTA as
indicated. (B) Effect of iron on native GST-mFXN/ISCU/NFS1/
ISD11 complex. GST-mFXN was co-expressed with mISCU,
mNFS1 and mISD11 and purified as in Fig. 2A. Iron or EDTA
was added during extraction and wash steps. Samples were loaded
on a 7.5% non-denaturing gel and stained with coomassie blue.
Western blot analysis and mass spectrometry analysis confirmed
that the upper band corresponds to a complex containing mFXN,
mISCU, mNFS1 and mISD11. (C) Effect of iron on the complex
formation. A bacterial soluble extract containing mNFS1, mISCU
and mISD11 was incubated with 0.1mM ferrous iron sulfate or
1 mM bathophenanthroline disulfonic acid (BP) in the presence of
10mM ascorbic acid (reducing condition) as indicated. Efficient
Fe
2+ chelation by BP was observed as the solution turned red,
accounting for the BP-Fe
2+ complex formation. Purified GST or
GST-mFXN was then added to each sample and further
incubated to allow GST-mFXN/ISCU/NFS1/ISD11 complex
formation. The samples were analysed by native PAGE and
coomassie blue staining and by western blot using a frataxin
antibody (IB). The ratio between frataxin as a monomer and
frataxin in the complex was not modified by iron excess or
depletion, indicating that the complex formation is not iron-
dependent. (D) Effect of different metals on the complex
formation. A bacterial soluble extract containing mNFS1, mISCU
and mISD11 was incubated with 0.05mM nickel sulfate, zinc
chloride, calcium chloride or magnesium sulfate as indicated.
Purified GST or GST-mFXN was then added to each sample and
further incubated to allow GST-mFXN/ISCU/NFS1/ISD11
complex formation followed by a GST tag purification. The
samples were then analysed by native and denaturing PAGE and
coomassie blue staining.
(JPG)
Figure S5 Characterization of fibroblast cell clones
carrying wild type or mutant FXN. (A) Transient transfec-
tion of wild-type FXN or mutants N146A, N146K, W155R and
W155A in COS-1 cells. Total extracts were loaded on a SDS-gel
and analyzed by Western blot using anti-frataxin and anti-tubulin
antibodies. For each construct, signals for precursor, intermediate
and mature frataxin are equivalent suggesting that the mutations
do not disturb the expression and the maturation process of the
protein. NT corresponds to non-transfected COS-1 cells. (B)
Genotyping on heterozygous L3/L- cell populations expressing
either wild type or mutant (N146A, N146K or mito81–210) hFXN
before (L3/L2) and after pEGFP-Cre transfection and clonal
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the number of clones obtained for each frataxin mutant and the
corresponding cellular and biochemical phenotypes observed. (D)
Determination of oxidative stress sensitivity of wild-type FXN and
mutants N146A and mito81–210 clones. Cells were incubated
with DHR123 and analyzed by FACS. The thin curves represent
the autofluorescence of cells without DHR123 treatment. The
black curves represent the fluorescence observed with no
exogenous stress, and the grey curves represent the fluorescence
induced after hydrogen peroxide treatment (20 mM; 30 min).
Experiments were done in duplicate on 4 clones of FXN, 3 clones
of N146A and 4 clones of mito81–210. I154F mutant clone was
used as a positive control. (E) Ultrastructural alterations in the
N146K clone observed by electron microscopy analysis. mt,
mitochondria; Lp, lipid droplet; mt-Fe, intramitochondrial iron
deposits; N, nucleus. (F) Transient transfection of wild-type hFXN
or mito81–210 in COS-1 cells. Total extracts (left panel) were
loaded on a SDS-gel and analyzed by Western blot using anti-
frataxin antibody. NT corresponds to non-transfected COS-1
cells. On the right panel, cellular fractioning of COS-1 cells
transfected with mito81–210. Cytosolic and mitochondrial frac-
tions were loaded on gel and analyzed using anti-frataxin antibody
by Western blot.
(JPG)
Figure S6 Purification and characterisation of the
FXN/NFS1/ISCU/ISD11 complex. (A) GST-mFXN was
co-expressed with mISCU, HIS-mNFS1 and mISD11 followed
by double purification using GSH and nickel columns. The
presence of the HIS tag on NFS1 had no effect on complex
formation (first and second lanes). The lane on the right shows the
complex obtained after co-expression, and purification using the
HIS tag of FXN-HIS with mISCU, mNFS1 and mISD11 on a
native gel. (B) Gel filtration with the GST-mFXN/ISCU/HIS-
NFS1/ISD11 complex. After purification using GSH and Nickel
columns, the sample was loaded and separated by gel filtration.
Sixty fractions were collected and fractions 2 to 40 were run on
SDS- and native-PAGE to determine the protein composition by
coomassie blue staining. Fractions 14 to 18 that contained the
complex were concentrated for the native mass spectrometry
analysis. Note that the signal observed for GST-mFXN after the
double purification is due to contamination on the nickel column
due to the large excess of GST-mFXN monomer present in the
sample before gel filtration. (C) ESI native mass spectrum of the
complex with GST-mFXN. The complex was purified as in
indicated in (A) and (B) and submitted to native mass spectrometry
analysis. The experimental molecular weight for each component
obtained in denaturing conditions were 10,722 Da, 14,576 Da,
41,047 Da and 45,553 Da for mISD11, mISCU, GST-mFXN
and HIS-mNFS1, respectively. A significant set of peaks
(corresponding to the multicharged ions) was detected correspond-
ing to a molecular weight of 237,130 Da. (D) Stoichiometry of the
quaternary complex. Comparison of the molecular weight (MW)
obtained with different combinations using the observed mass of
each component and the observed mass of the complexes. NFS1
was considered as a dimer, by analogy with the bacterial IscS and
NifS. The observed mass difference between the GST-mFXN/
mISCU/HIS-mNFS1/mISD11 complex and the mFXN-HIS/
mISCU/mNFS1/mISD11 complex indicates that there are 2
frataxins per complex. The ISCU:frataxin ratio is 1 as measured in
(F). The residual mass can be attributed to the presence of 3 or 4
ISD11 per complex. (E) Determination of the ISCU:frataxin ratio
within the complex. mISCU-HIS and mFXN-HIS were purified
by tag purification and gel filtration (S75). mISCU-HIS and
mFXN-HIS fractions were quantified using the theoretical
extinction coefficient at 280 nm of 9,970 M
21 cm
21 and
26,930 M
21 cm
21, respectively (http://expasy.org/tools/prot-
param.html). Both fractions were then used to generate standard
curves. mFXN-HIS/mISCU/mNFS1/mISD11 complex was
purified by coupling affinity tag purification and gel filtration
(S200) and loaded on a SDS gel. The quantity of frataxin and
mISCU was determined by densitometry after coomassie blue
staining, using a Chemi genius
2 bio imaging system and
GeneTools software (Syngene). The result is presented as the
average obtained from six independent experiments 6 SD. Note
that on the rare occasions when frataxin was less expressed, the
quantity of frataxin per complex was lower.
(JPG)
Figure S7 Purification of the mISCU/mNFS1/mISD11
ternary complex. (A) The mISCU-HIS/mNFS1/mISD11
complex was purified from co-expressing bacteria using HIS-tag
purification and gel filtration. Both the eluate (E) after HIS-tag
purification (left panel) and the fractions of the gel filtration (right
panel) were loaded on SDS-PAGE and analyzed by coomassie
blue staining. The ternary complex was isolated in fractions 5 to 7.
(B) The mISCUD72A-HIS/mNFS1/mISD11 complex was puri-
fied as in (A). The eluate (E) from the HIS-tag purification (left
panel) and the fractions of the gel filtration (right) panel were
loaded on SDS-PAGE and analyzed by coomassie blue staining.
More ternary complex could be obtained compared to wild type
mISCU (see (A)) in fractions 5 to 7, indicating that the D72A
mutation increases the affinity of mISCU for mNFS1/mISD11.
(JPG)
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